Department of Health and Exercise Science, Rowan University, Glassboro, NJ 08028, United States.
Cooper University Health Care, Cherry Hill, NJ 08002, United States.
Mult Scler Relat Disord. 2022 Jul;63:103817. doi: 10.1016/j.msard.2022.103817. Epub 2022 Apr 25.
Both upper and lower extremity motor symptoms are common in people with multiple sclerosis (PwMS) and there is a need to develop objective, reliable, and valid outcome measures. The aim of this study was to evaluate the reliability and external validity of the standard and novel isometric tests in the assessment of neuromuscular functioning in both upper (grip force; GF) and lower (knee extensors; KE) extremities in PwMS.
Twenty-nine relapsing-remitting PwMS (Expanded Disability Status Scale (EDSS)<6) completed isometric and functional tests in upper (grip force) and lower (knee extension) extremity in two separate visits. Isometric testing included maximum force (maxF), maximum rate of force development (maxRFD), and our recently developed novel brief force pulse protocol (BFP). The dependent variables of BFP included rate of force development and relaxation scaling factors (RFD-SF and RFR-SF), which quantifies an individual's ability to scale the rates of force development and relaxation with the magnitude of force pulse produced. PwMS also completed functional tests of upper (9-hole peg (9HPT), finger tapping (FTT)) and lower extremity (25-ft walk test (T25WT), timed up and go (TUG), 5-time sit-to-stand (5StS), and Multiple Sclerosis Spasticity Scale (MSSS-88)).
Most isometric outcome measures had high reliability (ICCs>0.87 and CVs<12%). In GF, both RFD-SF and RFR-SF had significant associations with 9HPT and FTT (r's between 0.49-0.55, p<0.05). In KE, while maxF, maxRFD, and RFD-SF were moderately correlated to some of the functional tests, the strongest correlations were observed for the RFR-SF (T25FW, r=0.71; TUG, r=0.60; 5StS, r=0.47; MSSS-88, r=0.60, and EDSS, r=0.71). Multiple linear regression analysis indicated that RFD-SF is the only predictor for 9HPT and RFR-SF is the only predictor of walking speed among the studied variables.
BFP protocol provides highly reliable and relevant outcome measures to evaluate both upper and lower extremity functioning in PwMS. Specifically, the ability to relax muscle forces quickly after a quick force production highly contributes to walking speed in PwMS.
多发性硬化症(MS)患者常同时出现上肢和下肢运动症状,因此需要开发客观、可靠和有效的结局测量指标。本研究旨在评估标准和新型等长测试在评估 MS 患者上肢(握力;GF)和下肢(伸膝肌;KE)神经肌肉功能方面的可靠性和外部有效性。
29 例复发缓解型 MS(扩展残疾状况量表(EDSS)<6)在两次单独就诊中完成了上肢(握力)和下肢(伸膝)的等长和功能测试。等长测试包括最大力(maxF)、最大力速(maxRFD)和我们最近开发的新型短暂力脉冲方案(BFP)。BFP 的因变量包括力速发展和放松标度因子(RFD-SF 和 RFR-SF),可量化个体产生力脉冲时以力脉冲幅度缩放力速发展和放松的能力。MS 患者还完成了上肢(9 孔钉测试(9HPT)、指敲击测试(FTT))和下肢(25 英尺步行测试(T25WT)、计时起立行走测试(TUG)、5 次坐站测试(5StS)和多发性硬化痉挛量表(MSSS-88))的功能测试。
大多数等长结局指标具有较高的可靠性(ICC>0.87,CV<12%)。在 GF 中,RFD-SF 和 RFR-SF 与 9HPT 和 FTT 均有显著相关性(r 值为 0.49-0.55,p<0.05)。在 KE 中,虽然 maxF、maxRFD 和 RFD-SF 与部分功能测试中度相关,但最强的相关性观察到 RFR-SF(T25FW,r=0.71;TUG,r=0.60;5StS,r=0.47;MSSS-88,r=0.60 和 EDSS,r=0.71)。多元线性回归分析表明,RFD-SF 是 9HPT 的唯一预测因子,RFR-SF 是研究变量中步行速度的唯一预测因子。
BFP 方案可提供高度可靠且相关的结局测量指标,用于评估 MS 患者的上肢和下肢功能。具体来说,快速产生力量后快速放松肌肉力量的能力高度有助于 MS 患者的步行速度。